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Abstract
Background and Objective: Bronchiolitis is the most common reason for admission to hospital in
the first year of life, with increasing hospitalization rates in Canada. Respiratory support with high-flow
nasal cannula (HFNC) is being routinely used in paediatric centres, though the evidence of efficacy
is continuing to be evaluated. We examined the impact of HFNC on intubation rates, hospital and
paediatric critical care unit (PCCU) length of stay (LOS), and PCCU admission rates in paediatric
tertiary centres in Canada.
Methods: We conducted a multicentre, interrupted time series analysis to examine intubation
rates pre- to postimplementation of HFNC for bronchiolitis. Data were obtained from the Canadian
Institute for Health Information database. Paediatric tertiary centres that introduced HFNC between
2009 and 2014 were included, and data were collected from April 2005 to March 2017.
Results: A total of 17,643 patients met inclusion criteria. There was no significant change in intubation rates after the introduction of HFNC. There was a significant increase in PCCU admission, with
a decrease in the PCCU LOS following the introduction of HFNC. There was no significant change in
average hospital LOS after HFNC was introduced.
Conclusions: This study adds to the evolving evidence showing that overall disease course is not
modified by the use of HFNC. The initiation of HFNC in Canadian paediatric centres resulted in no
significant change in intubation rates or average LOS in hospital, but had an increase in PCCU admissions. Careful monitoring of new technologies on their clinical impact as well as health care resource
utilization is warranted.
Keywords: Bronchiolitis; High-flow nasal cannula; Intensive care units; Intubation; Paediatric.

Bronchiolitis is an extremely common viral lower respiratory
tract infection affecting more than one-third of children less
than 2 years of age and is the most common reason for hospital
admission in the first year of life (1). Hospitalization rates for
bronchiolitis have been on the rise in Canada, leading to increases in health care expense, morbidity, impact on families,
and critical care resources (1). Clinical practice guidelines for

infants with bronchiolitis from Canada and the United States
advocate for the use of supportive care, including supplemental
oxygen, as the evidence for the majority of interventions currently used is equivocal (1).
Children with more severe bronchiolitis have poor pulmonary compliance and high pulmonary resistance, which lead
to increased respiratory effort and potential respiratory failure.
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Noninvasive ventilation (NIV) support (i.e., CPAP/BiPAP)
can be used to support respiratory function in bronchiolitis
to improve ventilation and oxygenation without the use of
an endotracheal tube, with its associated adverse events (2).
However, NIV support can be challenging to deliver due to
patient agitation, frequent air leaks, and pressure sores from the
mask interface (3).
High-flow nasal cannula (HFNC) is an alternative to NIV
that can be applied to provide respiratory support to patients
with bronchiolitis through high flows of heated, humidified
oxygen. It does not create a seal at the patient interface, and therefore, pressures delivered cannot be measured and the significance of the pressure provided has not yet been determined
(4). However, the HFNC interface is easier to configure than
NIV masks and is also generally considered more comfortable
and better tolerated by patients (4). The rapid adoption of
HFNC in bronchiolitis has outpaced the evidence, with recent
acceleration in investigation as to its efficacy. Physiologic studies have shown HFNC is associated with decreased work of
breathing and respiratory rate (5). However, it remains unclear
if HFNC has a clinical impact on disease course or severity, as
current studies have shown differing outcomes (6–11).
Intubation is an objective clinical outcome that represents a
severe disease course. The ability to prevent this outcome would
have a significant clinical impact for the patient in reduced invasiveness and iatrogenic complications, as well as resource and
financial savings to the health care system. Our primary objective was to examine the effect of the introduction of HFNC in
Canada on intubation rates for paediatric patients with bronchiolitis. We hypothesized that the introduction of HFNC has
resulted in decreased intubation rates. Our secondary objectives were to determine the impact of HFNC on paediatric
critical care unit (PCCU) admission rate, PCCU length of stay
(LOS), and total hospital LOS.

METHODS
Study design
We conducted a multicentre, interrupted time series analysis for
children <2 years old with bronchiolitis. Time series analysis is
a method of disease incidence prediction using past values to
detect and forecast trends, while controlling for variability in
the data. Paediatric tertiary care centres in Canada that introduced HFNC between 2009 and 2014 were included, and data
were collected from April 2005 to March 2017. The centres
included range in size and catchment area, and all centres are
regional paediatric trauma centres and have PCCU beds. The
smallest centre is the only tertiary care centre in the province,
with 45 inpatient paediatric beds, 8 PCCU beds, and a catchment area of 1.1 million. The largest centre is one of 4 paediatric
centres in the province with 300 inpatient paediatric beds, 41
PCCU beds, and a catchment area population of 5 million. This

study was approved by Western University’s Health Science
Research Ethics Board.

Data collection
Data were obtained from the Canadian Institute for Health
Information (CIHI) database. CIHI is a nationwide independent and not-for-profit organization that collects data from
various databases and provides de-identified data requested
(12). Data collected from centres in the Province of Quebec
were excluded, as they were not available through CIHI. Of the
remaining 10 Canadian paediatric centres, 9 had implemented
HFNC during our study period. Study participants were identified using the Canadian Coding Standards, specifically ICD10-CA codes for diagnosis data. Outcomes were measured
using Canadian Classification of Health Interventions (CCI)
codes for intervention data to capture intubation. LOS data (in
days) and level of care (ward versus PCCU) were also collected. Health administrative data from CIHI has been validated
for RSV-related disease, the most common cause of bronchiolitis, in capturing LOS, PCCU admission, and intubation (13).
Data to identify NIV use was not shown to be sensitive and was
therefore not captured in our study.

Inclusion/exclusion criteria
All patients with any discharge diagnosis of bronchiolitis identified by ICD10 class J21 with age <2 years old at admission
were included. We excluded infants who were <37 weeks gestation, or had chronic lung diseases, trisomy 21, congenital heart
disease, or immunodeficiency.

Outcome measures
The primary outcome was the intubation rate before and after
the first paediatric centre introduced HFNC in June 2009.
Secondary outcomes included rate of PCCU admission, hospital LOS and PCCU LOS. Additional demographic data
obtained included age, gender, and Respiratory Syncytial Virus
status.

Statistical analysis
SPSS v.24 (14) was used for all analyses, using ARIMA
(auto-regressive, integrated, moving average) modeling on
quarterly data over the study period to account for variability
and seasonal effects in the outcomes. All models were adjusted
as ARIMA (0,0,4), which accounted for best model fit. HFNC
was first introduced in June 2009; therefore, the start of the
intervention period was classified at the next available quarter
(September 2009).

RESULTS
There were 19,813 admissions for bronchiolitis over the study
period (April 2005 to March 2017). There were 2,216 patients
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excluded because of comorbidities, leaving 17,643 patients in
our analysis (Figure 1).
There was no change in intubation rates before and after the
introduction of HFNC in Canada (Figure 2a). However, the
PCCU admission rate increased relative to the trend prior to
HFNC introduction (Figure 2b). In particular, after the introduction of HFNC, there was an average increase in the PCCU
admission rate of 0.38% (SE=0.07%) with each additional
quarter.
Despite the increase in PCCU admission rate, there was a
decrease in average PCCU LOS. The PCCU LOS had an increasing trend prior to HFNC introduction (M per quarter=0.29%,
SE=0.09%, P=0.002) with a drop at the time of HFNC introduction (M=−3.29%, SE=0.96%, P=0.001), followed by a significant decrease (M per quarter=−0.29%, SE=0.10, P=0.007)
in the PCCU average LOS trend relative to the trend prior to
introduction of HFNC (Figure 2c). HFNC introduction was
not associated with a change in the overall average hospital LOS
trend relative to the trend prior to HFNC (Figure 2d).

DISCUSSION
This is the first study in Canada to examine HFNC impact on
intubation rate, as well as the study with the largest paediatric
HFNC cohort reported in the literature to date (N=17,643).
Despite the lack of rigorous scientific evidence, uptake of
HFNC has been rapid. Previous studies have shown that HFNC
is associated with a physiologic response leading to a reduced
respiratory rate and work of breathing (5,15). However, when
looking at disease course as represented by intubation, PCCU

Admissions to 9
centres June 2005March 2017
n = 19,813
exclusion criteria
met*
n = 2,216
Included in analysis
n = 17,643

5,862 pa ents
admi ed before
HFNC introduced

11,791 pa ents
admi ed a er
HFNC introduced

Figure 1. Patient flow diagram. *Excluded if prematurity, chronic lung disease, congenital heart disease, Trisomy 21, or immunodeficiency present.

admission or hospital LOS, findings have been conflicting
(6–9). Preliminary single-centre retrospective studies have
not shown consistent outcomes on intubation rates following
implementation of HFNC, with two centres showing decreased
intubation rates (6,7) and one showing no effect (10). A recent
multicentre randomized control trial in bronchiolitis managed
outside of the PCCU, though not powered to look at intubation, showed that those who received HFNC had lower rates of
escalation of care than those treated with standard oxygen therapy (8). Overall, we found that intubation rate did not change
after HFNC was introduced across the country. Our study adds
to the body of evidence suggesting that HFNC does not impact
bronchiolitis disease course, as captured by these outcome
measures.
It is important to continually evaluate the effect of new treatment modalities on hospital resource utilization and clinical
outcomes, because if not measured, many unintended consequences can develop. Implementation of new technology can
have secondary resource allocation consequences that were
not initially predicted. As mentioned, HFNC introduction did
coincide with increasing PCCU admission rates and a decrease
in average LOS in the PCCU. In Canada, HFNC use for bronchiolitis has had significant uptake over the past decade, with
seven of the nine centres studied using it exclusively in the
PCCU during our study period; this may have contributed to
the increase in PCCU admissions. PCCU admission and LOS
outcomes have a significant impact on patient morbidity and
mortality, patient and family experience, as well as health care
resource allocation and expenditure. Recent literature suggests
HFNC may not be the optimal form of NIV for patients with
severe bronchiolitis in the PCCU setting (11). Rather, HFNC
may be best utilized to prevent those with moderate bronchiolitis from progressing to the point of requiring higher levels of
critical care monitoring (8,9).
It is unknown if there are factors that might affect admission
rates to PCCU in Canada that were not measured in our study,
such as trends in annual virus severity or quality improvement
initiatives that looked at optimizing patient hospital flow. It
will be beneficial to look at the impact that HFNC implementation on general paediatric wards has on PCCU admission
rates and resource utilization in Canada. Although we would
hypothesize that the implementation of a HFNC ward policy
would help decrease PCCU utilization, it has been suggested
that implementing a HFNC ward policy does in fact not impact
PCCU resource utilization (10). Future randomized studies are
required to better delineate these clinical and economic outcomes, especially since this study adds to the evolving evidence
showing that overall disease course is not modified by the use
of HFNC.
The current body of evidence may lead us to consider that
the role of HFNC in a tertiary care centre is to prevent and rescue some of these patients with moderate bronchiolitis from
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Figure 2. (a) Intubation rate with overall predicted trend pre- and post-high-flow nasal cannula (HFNC) introduction (P=0.39). P-value represents the difference in pre- and postimplementation slope. (b) Paediatric critical care unit (PCCU) admission rate with overall predicted trend pre- and post-HFNC introduction (P<0.001). P-value represents the difference in pre- and postimplementation slope. (c) Average PCCU length of stay (LOS) in days with overall predicted
trend pre- and post-HFNC introduction (P=0.01). P-value represents the difference in pre- and postimplementation slope. (d) Average hospital LOS in days
with overall predicted trend pre- and post-HFNC introduction (P=0.27). P-value represents the difference in pre- and postimplementation slope.

needing to be transferred to the PCCU. Consequently, many
centres are adapting policies in order to increase the use of
HFNC on the medical wards. Our study reinforces that disease
severity is unchanged (as witnessed by unchanged intubation
and hospital LOS); judicious continued monitoring should be
advocated for in patients placed on HFNC in order to detect
changes in patient state. Use of HFNC should not cloud clinical judgment, and criteria for referral to the PCCU should be
upheld. Patients on HFNC who remain in respiratory distress
should be as vigilantly monitored with timely referral to critical
care services as those without HFNC.
Our study was limited by the nature of its design being
retrospective. There was no control population or adjustment for disease severity, though we accounted for this in our
study design by using a time series analysis. Implementation
of HFNC was not simultaneous across centres, and therefore,
an implementation time of June 2009 was chosen, as this was
when the first centre introduced HFNC. This was chosen to be
inclusive of all centres that introduced HFNC. This study only
included previously well infants. Because we used a database
to collect our data, we were unable to gather clinical measures
such as respiratory rate or heart rate that could help to better
capture clinical response to HFNC. We were also unable to
gather time data for duration of intubation. This study only

included tertiary care centres where PCCUs were located in
the same institution and, therefore, cannot be applied to the
community hospital setting.

CONCLUSION
Using an interrupted time series analysis, we found that initiating HFNC in Canadian paediatric centres resulted in no
significant change in intubation rates or average LOS in hospital from April 2005 to March 2017, but was associated with an
increase in PCCU admissions and a decrease in PCCU average
LOS. These findings suggest that HFNC does not prevent intubation in patients with bronchiolitis, as has been previously suggested (6,7). Safety studies and judicious clinical criteria for use
of HFNC on the ward in the tertiary care setting may address
rising PCCU admission rates. Careful monitoring of new technologies is warranted in terms of their clinical impact as well as
health care resource utilization.
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